Member Info for B2HS2L

Mobile testing will probably be a good way of selling the q16 / q32 instruments.

Nice to have claims of IP ownership verified for the following two granted Affimer patent applications.
Note the expiration dates that would come into play in any takeover negotiation(!) :

https://patents.google.com/patent/EP2279205B1/en?oq=2%2c279%2c205
European Application granted and Publication of EP2279205B1 = 2016-08-17
Anticipated expiration 2029-04-16

https://patents.google.com/patent/US9447170B2/en?oq=14%2f478%2c910
Publication of US9447170B2 = 2016-09-20
Anticipated expiration 2029-04-16

https://www.fda.gov/media/136823/download
FDA display Instructions for use ver 1.02 - 'Bronchoalveolar Lavage'

https://www.who.int/diagnostics_laboratory/eul_0489_185_00_path_covid19_ce_ivd_ifu_issue_2.0.pdf?ua=1
World Health Organisation display Instructions for use ver 2.0 - Sputum

https://www.genesig.com/assets/files/Path_COVID_19_CE_IVD_IFU_Issue_3.pdf?timestamp=1591812525
Genesig display Instructions for use ver 3.0 - Sputum

So Sputum it is, unless your looking at the FDA document.

Here's hoping for great news tomorrow.

Seems 'Sputum' is not correct - from the Primerdesign document (Instructions for Use) found on the FDA EUA website:

https://www.fda.gov/media/136823/download

Primerdesign Ltd COVID-19
genesig® Real-Time PCR assay

For Emergency Use Authorization Only

Instructions for Use (IFU) Issue 1.02

1. Intended Use (page 4)

The Primerdesign Ltd COVID-19 genesig® Real-Time PCR assay is a real-time RT-PCR assay
intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasal,
oropharyngeal swab specimens, and bronchoalveolar lavage from patients suspected of
COVID-19 by their healthcare provider. Testing is limited to laboratories certified under
the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to
perform high complexity tests.

Ends.

A search of the document for 'sputum' is not found.

Whatnonewsyet: from your 15:19 post -

"PrimeDesign kit can be used with saliva and nasal swabs. Extract from:-
PrimerdesignTM Ltd
Coronavirus COVID-19
genesig® Real-Time PCR assay

Makes NCYT product pretty well placed.

The Coronavirus COVID-19 (CE IVD) genesig® Real-Time PCR kit has been validated for use
with sputum, oropharyngeal swab and nasopharyngeal swab samples"

Sputum isn't only saliva.

https://www.google.com/search?client=avast&q=sputum+meaning

noun: sputum
a mixture of saliva and mucus coughed up from the respiratory tract, typically as a result of infection or other disease and often examined microscopically to aid medical diagnosis.

jm2c.

Verbaly kick derampers in the crotch as much as you like guys, but if you do it for more than ten minutes after they
posted their rubbish, you are serving their agenda.
Don't allow this board to be filled with invective, but rather concentrate on the excellent research continuing here.

To all those researching Friday night on the above thread:

This is a read-across from a SNG board post at 14:04 yesterday, investigating ownership of SNG shares.

https://www.morningstar.com/stocks/xlon/sng/ownership. - becomes https://www.morningstar.com/stocks/xlon/ncyt/ownership - the change makes the search applicable to NCYT.
If you move the horizontal bar you can see the recent buy & Sell history for each Fund/II.

The data displayed on the Morningstar screen doesn't tally with much discussed on Friday night.

I don't want to muddy the waters, but it is relevant to the search for information.

I would pay attention to the 'today' thread starting early Friday evening, as there is some first class research concerning company ownership. Thanks to all involved.

Hi Ghia.

"The PCR test looks for 3 distinct signals in each sample (i) a positive or negative COVID19 signal based off E and N genes, (ii) an internal control signal to tell you that the PCR reaction has worked and (iii) an human “RNaseP” signal that tells you there is human DNA in the sample. Ideally, you get all 3 amplifying in a positive case. If you get no COVID signal and also get no RNaseP signal, good chance it’s not the best sample, or no sample at all."

If you don't have one of the following:

i) a positive or negative COVID19 signal based off E and N genes,
ii) an internal control signal to tell you that the PCR reaction has worked
iii) an human “RNaseP” signal that tells you there is human DNA in the sample.

...then I would assume the sample cannot be further tested, because the lack of any one of these signals is a show stopper.

I notice that i) includes the use of more than one gene, - we know the Primerdesign test uses just one gene, and we don't know if using one more gene is an easy task.
The Primerdesign assay is one if the fastest PCR tests available, so to detect and use more signals may increase processing time.

The company must be aware of the incorrect swabbing issue, as it will have had numerous discussions on the issue.
I trust the company to assure that if it is possible to modify a test to indicate when human error has occured during swabbing, then they would take steps to rectify is possible.

i neglected to include a smiley face to show my warm, cuddly side... : )

like that!

++++

i have included my backside to show my revulsion at the thought of being considered in league with Macron...(][)

com ca

"But I guess my question still stands will Primer add additional checks in their test to identify where Human Error May have given a false negative."

Ghia, I don't think I have read anything which states the company is working on such additional checks, - or even if it is possible to detect human error in gathering the samples.

https://blog.primerdesign.co.uk/1-vs-2-gene-covid-19-assay-find-out-from-our-experts-which-is-best-for-testing-during-the-covid-19-pandemic/

It explains why the French Govnt is wrong to require a 2 gene approach to SARS-Cov-2 detection:

"To ensure the COVID-19 primers and probe remain specific to detect SARS-CoV-2 genomes, Primerdesign’s Bioinformaticians review daily the SARS-CoV-2 sequence submissions on the GISAID EpiCoV database.

!!Each new sequence presents a risk to kit detection and false negatives for competitors without surveillance programs.!! The potential risk of false negatives increases with 2/3 target assays meaning a patient with a false negative will potentially be back in the community affecting the general population by spreading COVID19.

“Unlike the SARS outbreak of the early 2000s, the amount of sequencing conducted by diagnostic laboratories around the world is unprecedented. The GISAID database EpiCoV currently contains over 6,000 sequences, of which are good quality full length genome sequences. It enables us to check our assay design against the database daily, to ensure that mutations are not accumulating in the target region of the primers and probes. We are therefore confident that our assay will still detect 100% of the sequences available, giving our customers confidence that the easy to use one assay approach will not miss any positive cases due to mutations. It also won’t give conflicting results which may arise if mutations accumulate in one of two assays, leading to a decrease in sensitivity of that assay.” Gemma Stokes, Bioinformatician Scientist Primerdesign.

“If clinical diagnosis is being performed, complete confidence is needed in your test. At Primerdesign our bioinformatics team check our COVID-19 CE design daily against all globally published sequence information for assurance in a comprehensive SARS-CoV-2 detection profile. Ultimately, we have complete confidence in our unique design and product. We therefore do not need to target multiple genes. ” Adam Herridge, Product Manager Primerdesign."

VanV has stated the our bioinformaticians can confirm the COVID-19 assay primers and probe still show 100% homology with the latest SARS-CoV-2 sequences in his 12:56 post, and latest homology report can be found here:

https://twitter.com/PrimerdesignLtd/status/1267389572788469761/photo/1

The marketing team have a report available, proving assay efficacy updated weekly, that no other assay supplier bothers to provide.

Ghia 12:17 - Has there been any comment from the company on whether they will adapt their test design
in light of the rejection from the French Government?

https://blog.primerdesign.co.uk/1-vs-2-gene-covid-19-assay-find-out-from-our-experts-which-is-best-for-testing-during-the-covid-19-pandemic/

Ghia, - It seems the French Govnt. needs to get with the program, (modernise its views).

Here Primerdesign discusses view on 1, 2 and 3 gene testing.

https://equityincome.linkfundsolutions.co.uk/media/kn3h2q0p/05th-june-2020-investor-letter.pdf

For you information guys, lifted directly from another BB.

I hope they increase the radius from Southampton to > 40 miles to get sufficient home test volunteers soon.

He hasnt been seen, because he's been abducted.

They'll be lowering the cargo door of the Hercules transport soon,

hants will be pushed out the back with no parachute from 20,000 feet because...

HE MENTIONED HE'S READ THE EMAIL...

++++

The moral here is don't chase daft stories...

Night all - don't S**t the bed...

I don't know what info was shared, and I don't care.

I saw a much better story played out on BBC1 at 9pm tonight (Ambulance).

Cameras rolling in the control centre and call centre staff receive a call.

Caller: I'm bleeding - quite a lot, (sounding pained).

staff: Where from?

Caller: My foreskin, - it's split.

staff: How'd that happen

Caller: Well errr, kinda, sortof....W*nking...

No idea if it was for real, but nearly wet myself.

Good Luch AVCT shareholders, lets hope we don't have to wait too long for updates..

"We are very pleased to have added a significant strategic US investor to our register."

Perhaps a company that can assist greatly with the task of developing the Neutralising Affimer Therapy (NAT) ;)

EXMEX:
From RNS 07.10.2019

New molecular respiratory panel ready for the US market

"Novacyt's molecular business unit Primerdesign, has completed the design and development of the molecular respiratory panel based on a 384 well plate format for use by its North American business partner in their CLIA approved diagnostic testing laboratory network. Primerdesign has designed the multiplex test to identify 37 respiratory pathogens, which makes it one of the most comprehensive respiratory panels available in the market today. In addition to identifying a large number of respiratory disease pathogens, the new diagnostic product has been designed with proprietary freeze-drying technology to stabilise the product to optimise its ease of use and performance."

"Primerdesign will supply this product under a five year manufacturing agreement as its partner launches the new respiratory panel in the US market through its own clinical testing laboratories to provide a Laboratory Developed Diagnostic test result for its customers. The initial order for $105,000 has been received by Primerdesign to supply its US partner."

For me, the above points to Primerdesign providing the panel(s) to the partner for use in their own clinical testing laboratories. Not sure the partner is selling them.

Strikes me though that this might be the same US partner that Primerdesign is working with for Covid -19 test kit sales.

Paulo - From RNS 02.06.2020:

"Novacyt is now selling its COVID-19 test into more than 130 countries, with the top two countries being the UK and Germany."

"Following completion of a formal evaluation of the Primerdesign COVID-19 test by the Medicines Control Authority of Zimbabwe and a successful tender process, Zimbabwe's Ministry of Health and Child Care has awarded Primerdesign with a contract for the supply of 1.5 million tests. Outside the UK, this is the largest contract secured by Novacyt to date"

For both quotes to be correct:

1 Germany must be buying regularly, with no orders larger than 1.5 million tests (not test kits.)

2 Zimbabwe has provided just one contract for 1.5 million tests (not test kits.)

Any other interpretations?

As an aside, and with nobody worldwide sure whether to expect a second spike, or for test and trace to work better than expected, it makes sense to receive smaller quantities of tests, to ensure that fresh test kits are always available.

That would work for both German and Zimbabwe orders.